Profitelligence Profitelligence · Filing Ledger Open MTSR research →

Form 8-K · Current Report · Filed 2025-11-10

Metsera, Inc. Amends Merger Agreement with Pfizer Inc.

On November 7, 2025, Metsera, Inc. announced an amendment to its previously disclosed merger agreement with Pfizer Inc. The amendment increases the upfront cash consideration from $47.50 to $65.60 per share and adjusts the contingent value rights (CVR) from up to $22.50 to up to $20.65 per share. The amendment also modifies certain financial terms and milestones related to the merger. Metsera issued a press release announcing the signing of the amendment.

Filer
MTSR MTSR
Filed
Accession
0001193125-25-273292
CIK
0002040807
Signal
High impact
Source
Official filing on sec.gov ↗

Items reported

Item 1.01

Entry into a Material Definitive Agreement

Material Agreement Amendment M&A Agreement
Item 8.01

Other Events

Corporate Update

Market reaction

Close before filing

$83.18

Next session

-14.9%

Since filing

-15.2%

Latest close

$70.50

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from MTSR reporting the same item, with the next session's move:

Metsera Responds to Pfizer Litigation Ruling+11.4%
Metsera Declares Novo Nordisk Proposal as Superior Company Proposal+17.5%
Metsera Responds to Pfizer Litigation Amid Acquisition Proposal+16.1%
Metsera, Inc. Responds to Pfizer Litigation and Announces Proposed Acquisition-4.7%
Metsera Declares Novo Nordisk Proposal as Superior Company Proposal+20.7%

Never miss another MTSR filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts